Add office photos
Employer?
Claim Account for FREE
DIVI'S Laboratories
3.6
based on 1.6k Reviews
Video summary
Company Overview
Company Locations
Working at DIVI'S Laboratories
Company Summary
DIVI'S Laboratories is a major player in the global API market, focusing on high-quality active pharmaceutical ingredients for various international markets.
Overall Rating
3.6/5
based on 1.6k reviews
8% below
industry average
Highly rated for
Salary
Critically rated for
Promotions, Work satisfaction, Company culture
Work Policy
Work from office
91% employees reported
Rotational Shift
45% employees reported
Strict timing
60% employees reported
No travel
57% employees reported
View detailed work policy
Top Employees Benefits
Free meal
95 employees reported
Job/Soft skill training
87 employees reported
Health insurance
63 employees reported
Office gym
28 employees reported
View all benefits
About DIVI'S Laboratories
Founded in1990 (35 yrs old)
India Employee Count5k-10k
Global Employee Count10k-50k
India HeadquartersHyderabad/Secunderabad, Telangana, India
Office Locations
--
Websitedivislabs.com
Primary Industry
Other Industries
--
Are you managing DIVI'S Laboratories's employer brand? To edit company information,
claim this page for free
View in video summary
Divi’s Laboratories Limited is one of the largest API companies in the world, with ~$730M in revenue and exporting to more than 95 countries.
Mission: To be a good corporate citizen and not only add value in our core competency areas of Pharma but also serve the community at large through social, educational and environmental initiatives that would establish strong foundations for a better tomorrow.
Vision: To maintain leadership in custom synthesis of APIs and Intermediates for health care and life sciences industry and to be one of the top companies world-wide in the domain. To develop generic APIs for the late life cycle needs of the Industry.
Report error
Managing your company's employer brand?
Claim this Company Page for FREE
DIVI'S Laboratories Ratings
based on 1.6k reviews
Overall Rating
3.6/5
How AmbitionBox ratings work?
5
562
4
460
3
280
2
83
1
168
Category Ratings
3.8
Salary
3.7
Job security
3.4
Work-life balance
3.4
Skill development
3.2
Company culture
3.2
Work satisfaction
3.1
Promotions
DIVI'S Laboratories is rated 3.6 out of 5 stars on AmbitionBox, based on 1.6k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at DIVI'S Laboratories
based on 1.5k reviews
3.8
Rated by 187 Women
Rated 3.8 for Job security and 3.7 for Salary
3.6
Rated by 1.3k Men
Rated 3.8 for Salary and 3.7 for Job security
Work Policy at DIVI'S Laboratories
based on 188 reviews in last 6 months
Work from office
91%
Hybrid
6%
Permanent work from home
3%
DIVI'S Laboratories Reviews
Top mentions in DIVI'S Laboratories Reviews
+ 5 more
Compare DIVI'S Laboratories with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 3.6/5 based on 1.6k reviews | 4.0/5 based on 7.4k reviews | 4.1/5 based on 6.8k reviews | 4.1/5 based on 7.6k reviews |
Highly Rated for | Salary | Skill development Salary Work-life balance | Salary Skill development Job security | Skill development Salary Work-life balance |
Critically Rated for | Promotions Company culture Work satisfaction | Promotions |  No critically rated category | No critically rated category |
Primary Work Policy | Work from office 91% employees reported | Work from office 74% employees reported | Work from office 67% employees reported | Work from office 72% employees reported |
Rating by Women Employees | 3.8 Good rated by 187 women | 3.9 Good rated by 856 women | 4.0 Good rated by 516 women | 4.0 Good rated by 778 women |
Rating by Men Employees | 3.6 Good rated by 1.3k men | 4.0 Good rated by 6.2k men | 4.1 Good rated by 6k men | 4.1 Good rated by 6.5k men |
Job security | 3.7 Good | 3.5 Good | 3.9 Good | 3.7 Good |
View more
DIVI'S Laboratories Salaries
DIVI'S Laboratories salaries have received with an average score of 3.8 out of 5 by 1.6k employees.
Chemist
(798 salaries)
Unlock
₹1.8 L/yr - ₹6 L/yr
Supervisor
(567 salaries)
Unlock
₹1.8 L/yr - ₹5.6 L/yr
Production Chemist
(549 salaries)
Unlock
₹1.8 L/yr - ₹5.7 L/yr
Analyst
(395 salaries)
Unlock
₹2 L/yr - ₹5.1 L/yr
Production Supervisor
(347 salaries)
Unlock
₹1.9 L/yr - ₹6 L/yr
Maintenance Engineer
(165 salaries)
Unlock
₹2 L/yr - ₹6 L/yr
Quality Analyst
(135 salaries)
Unlock
₹1.8 L/yr - ₹5.2 L/yr
QC Analyst
(132 salaries)
Unlock
₹1.9 L/yr - ₹5 L/yr
Maintenance Supervisor
(128 salaries)
Unlock
₹1.9 L/yr - ₹5.3 L/yr
Quality Control Analyst
(116 salaries)
Unlock
₹1.9 L/yr - ₹5.5 L/yr
DIVI'S Laboratories Interview Questions
DIVI'S Laboratories Jobs
Popular Designations DIVI'S Laboratories Hires for
Cost Accountant
Create job alerts
QC Analyst
Create job alerts
Production Chemist
Create job alerts
DIVI'S Laboratories News
View all
Q1 Results Live: Trent, Bajaj Auto, Raymond, Hero MotoCorp In Focus Today
- Several companies including Trent Ltd., Bajaj Auto, Raymond, Hero MotoCorp, BHEL, and others are set to announce their earnings for the first quarter on Wednesday.
- Divi's Laboratories reported a surge in profits for Q1FY26, with revenue up 13.8% and net profit up 26.7% year-on-year.
- BHEL's share prices marked losses ahead of posting results, trading down over 3%.
- Trent shares were trading higher before the earnings announcement, showing a gain of about 0.73%.
Bloomberg Quint | 6 Aug, 2025
Stock Market Live: GIFT Nifty Implies Flat Open; RVNL, Sun Pharma, Shipping Corp In Focus
- Asian share indices were trading lower, which may weigh on Nifty 50 and Sensex.
- GIFT Nifty was down 0.27%, implying a higher open for the Nifty 50 index.
- Traders are focusing on Divi's Laboratories Ltd., Premier Energies Ltd., KEC International Ltd., Shipping Corp of India, and Sun Pharmaceutical Industries.
- NSE Nifty 50 closed lower by 0.17% and BSE Sensex ended 0.24% down.
Bloomberg Quint | 19 May, 2025
Q4 Results Live: Divi's Labs, Zen Technologies, Data Patterns & Happy Forgings In Focus Today
- 56 companies, including Divi's Laboratories, Zen Technologies, Data Patterns, and Happy Forgings, will publish their fourth quarter earnings.
- Live updates on Q4 earnings available on May 17.
- The companies like Divi's Laboratories, Zen Technologies, Data Patterns, and Happy Forgings are in focus today.
- Stay tuned for the latest updates on stock market, business news, and IPO on NDTV Profit.
Bloomberg Quint | 17 May, 2025
Stocks To Buy Today: Tata Steel, Prestige, Divis Laboratories, Max Healthcare, Balkrishna Industries
- Analysts have recommended 'buy' calls on stocks like Tata Steel Ltd., Prestige Estates Ltd., Divis Laboratories Ltd., Max Healthcare Institute, and Balkrishna Industries.
- Stock recommendations include target prices and stop losses set by experts such as Kunal Rambhia, Shrikant Chouhan, and Aditya Agarwala.
- Positive outlook expressed for Tata Steel and Prestige Estates, while cautious sentiments for Divis Laboratories and Max Healthcare Institute were highlighted.
- Investors are advised to conduct thorough research or consult their financial advisors before making any investment decisions.
Bloomberg Quint | 7 May, 2025
Heard On The Street: Dealers Spot Action In PNB Housing, Axis Bank, Dr. Reddy’s, Kotak Mahindra Bank And More
- Dealer chatter hints at Carlyle potentially exiting its stake in PNB Housing and Axis Bank preparing for a QIP, with notable HNI activity in Dr. Reddy’s, Divis Lab, and Kotak Mahindra Bank.
- Activity in dealing rooms highlights significant cues in PNB Housing, Axis Bank, Dr. Reddy’s, Divis Lab, and Kotak Mahindra Bank as institutional flows and corporate actions are monitored.
- Dealers suggest Carlyle Group looking to sell 10.4% stake in PNB Housing, Axis Bank planning Rs 20,000 crore equity fundraise, and HNIs positioning to sell Dr. Reddy’s and buy Divis Lab.
- Kotak Mahindra Bank's stock price stands out positively despite Nifty Bank index weakness, yet domestic institutional sell flows noted at higher levels, while JSPL sees accumulation before Q4 earnings for mine opening expectations.
Bloomberg Quint | 30 Apr, 2025
Heard On The Street: Dealers Spot Action In Tata Technologies, Eternal, Divis Lab And Bandhan Bank
- Tata Technologies: Large, high-net-worth individuals are selling shares in anticipation of potential block deals post-Q4 numbers.
- Bandhan Bank: High-net-worth individuals are taking positional sell trades ahead of Q4 numbers.
- Eternal (formerly known as Zomato): Share prices continue to be under pressure on the foreign institutional desk.
- Divis Lab and JSPL: Domestic institutional investors have been buying into Divis Laboratories and Jindal Steel & Power.
Bloomberg Quint | 28 Apr, 2025
Stocks in focus today: 21 April, 2025
- Adani Ports and SEZ Ltd has acquired Abbot Point Port Holdings Pte Ltd in a $2.4-billion non-cash deal.
- BHEL reports a 19% increase in revenue and records its highest-ever order inflows at ₹92,534 crore for FY 2024-25.
- ITC to acquire Sresta Natural Bioproducts for ₹472.50 crore to expand its organic food products segment.
- NIIT to purchase additional shares to fully acquire IFBI, making it a wholly-owned subsidiary.
- Voltas receives show cause notice for allegedly short-paying customs duty of ₹24.81 crore on imported items.
- ABB plans to spin off its Robotics division and start trading as a separate entity in Q2 2026.
- Oberoi Realty reports a 31% rise in sales bookings to ₹5,266 crore for the last financial year.
- Delhivery and Ecom Express seek CCI approval for a ₹1,400-crore deal for Delhivery to acquire a controlling stake in Ecom Express.
- JB Chemicals gets USFDA approval to market generic medication for high blood pressure.
- Divi’s Laboratories signs supply agreement with a global pharmaceuticals firm for advanced intermediates.
HinduBusinessLine | 21 Apr, 2025
Stocks To Watch Today: Infosys, HDFC Bank, ICICI Bank, Adani Ports, GAIL, Kolte-Patil Developers
- Stocks to watch today include Infosys, HDFC Bank, ICICI Bank, Adani Ports, GAIL, and Kolte-Patil Developers.
- Other stocks in focus before trading are Divi’s Laboratories, Zydus Lifesciences, and Tata Consultancy Services.
- Adani Ports announced acquisitions in Australia to boost cargo capacity significantly by 2030.
- Kolte-Patil Developers reported impressive fiscal 2025 sales and growth in project launches and collections.
- Zydus Lifesciences and Divi's Laboratories entered strategic agreements for technology commercialization and capacity expansion.
- GAIL faces a review of its integrated network tariff by the Petroleum and Natural Gas Regulatory Board.
- HDFC Bank and ICICI Bank posted their Q4FY25 earnings with positive growth in net profit and NPA figures.
- Yes Bank, HDFC Life Insurance, Infosys, Tata Elxsi, and other companies shared their financial results for Q4FY25.
- Earnings of companies like Mastek Ltd., Just Dial, Jio Financial Services, and more were also highlighted.
- Various developments, appointments, acquisitions, and financial outcomes across different sectors were reported for the day.
Bloomberg Quint | 21 Apr, 2025
Stock Market Today: All You Need To Know Going Into Trade On April 21
- India's benchmark equity indices closed higher for the third consecutive session on Thursday, with NSE Nifty 50 rising 1.77% and BSE Sensex going up by 1.96% to record their best week in four years.
- Foreign portfolio investors continued to be net buyers of Indian equities while domestic institutional investors were net sellers on Thursday.
- Several notable earnings reports included HDFC Bank, ICICI Bank, Yes Bank, HDFC Life Insurance, Infosys, and Tata Elxsi, among others.
- Stocks to watch included Jubilant Pharmova, Shree Cement, Biocon, BHEL, Vedanta, Cipla, Divi’s Laboratories, and National Fertilizers, among others.
- In trading tweaks, price band changes were noted for Diffusion Engineers, while Nifty April Futures saw an increase and a fall in open interest.
- The Indian rupee appreciated by 31 paise against the US dollar, closing at 85.38, supported by foreign inflows and stable market sentiment.
- Key developments in bulk deals and trading tweaks were observed for Coforge, Fusion Finance, Hathway Cable & Datacom, and others in the market.
- Overall, the stock market witnessed positive movements, with key indices performing well and notable corporate updates impacting investor sentiment.
- Various sectors and companies reported financial results, strategic investments, product launches, and regulatory approvals, influencing market dynamics.
- The market closed amidst a positive outlook, with key highlights including the rupee's appreciation, trading cues, and notable moves in the stock market.
- In the midst of several corporate actions and market developments, investors remained attentive to earnings reactions, stock movements, and upcoming board meetings.
Bloomberg Quint | 21 Apr, 2025
Divi's Laboratories Inks Supply Pact With Global Pharmaceutical Entity
- Divi's Laboratories has signed a supply agreement with a global pharmaceutical entity.
- The long-term agreement involves manufacturing and supplying advanced intermediates based on agreed commercial terms.
- Divi's Laboratories expects significant revenue contribution from this agreement but has not disclosed the identity of the partner.
- The company plans to invest between Rs 650 crore to Rs 700 crore for capacity addition at its manufacturing facilities, to be funded from internal accruals.
Bloomberg Quint | 18 Apr, 2025
Powered by
DIVI'S Laboratories Offices
Compare DIVI'S Laboratories with
Cipla
4.1
Dr. Reddy's
4.0
Sun Pharmaceutical Industries
4.1
Lupin
4.1
Zydus Lifesciences
4.0
Aurobindo Pharma
4.0
Macleods Pharmaceuticals
3.6
Alembic Pharmaceuticals
4.0
Abbott
4.1
Glenmark Pharmaceuticals
3.8
Ipca Laboratories
3.9
Alkem Laboratories
3.9
Torrent Pharmaceuticals
3.9
Ajanta Pharma
3.9
Akums Drugs & Pharmaceuticals Limited
4.3
Laurus Labs
4.3
Cadila Pharmaceuticals
3.4
Pfizer
3.9
Wockhardt
3.8
Granules India Limited
3.8
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to DIVI'S Laboratories
Cipla
Manufacturing, Pharma
4.1
• 7.6k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.4k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 6.8k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.7k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.0
• 6.6k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5.3k reviews
Macleods Pharmaceuticals
Biotech & Life sciences, Pharma
3.6
• 3.7k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.4k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.3k reviews
Glenmark Pharmaceuticals
Pharma
3.8
• 3.2k reviews
Ipca Laboratories
Pharma
3.9
• 3.2k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 3.1k reviews
DIVI'S Laboratories FAQs
When was DIVI'S Laboratories founded?
DIVI'S Laboratories was founded in 1990. The company has been operating for 35 years primarily in the Pharma sector.
Where is the DIVI'S Laboratories headquarters located?
DIVI'S Laboratories is headquartered in Hyderabad/Secunderabad, Telangana.
How many employees does DIVI'S Laboratories have in India?
DIVI'S Laboratories currently has more than 9,700+ employees in India. Production, Manufacturing & Engineering department appears to have the highest employee count in DIVI'S Laboratories based on the number of reviews submitted on AmbitionBox.
Does DIVI'S Laboratories have good work-life balance?
DIVI'S Laboratories has a work-life balance rating of 3.4 out of 5 based on 1,500+ employee reviews on AmbitionBox. 34% employees rated DIVI'S Laboratories 3 or below, while 66% employees rated it 4 or above for work-life balance. This rating suggests that while some employees recognize efforts towards work-life balance, there is scope for improvement based on employee feedback. We encourage you to read DIVI'S Laboratories work-life balance reviews for more details.
Is DIVI'S Laboratories good for career growth?
Career growth at DIVI'S Laboratories is rated as moderate, with a promotions and appraisal rating of 3.1. 34% employees rated DIVI'S Laboratories 3 or below, while 66% employees rated it 4 or above on promotions / appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading DIVI'S Laboratories promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in DIVI'S Laboratories?
Working at DIVI'S Laboratories comes with several advantages and disadvantages. It is highly rated for salary & benefits. However, it is poorly rated for promotions / appraisal, work satisfaction and company culture, based on 1,500+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
85 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
